User login
In July 2012, cetuximab was approved for use in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (mCRC) as determined by Food and Drug Administration-approved tests. A companion diagnostic, Therascreen KRAS RGQ PCR Kit for determining KRAS mutation status was approved concurrently with the cetuximab approval. The test is a real-time polymerase chain reaction assay that detects 7 mutations of the KRAS gene; tumors with none of these mutations are considered wild-type KRAS tumors.
*For PDFs of the full article and accompanying Commentary, click on the links to the left of this introduction.
In July 2012, cetuximab was approved for use in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (mCRC) as determined by Food and Drug Administration-approved tests. A companion diagnostic, Therascreen KRAS RGQ PCR Kit for determining KRAS mutation status was approved concurrently with the cetuximab approval. The test is a real-time polymerase chain reaction assay that detects 7 mutations of the KRAS gene; tumors with none of these mutations are considered wild-type KRAS tumors.
*For PDFs of the full article and accompanying Commentary, click on the links to the left of this introduction.
In July 2012, cetuximab was approved for use in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) for first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing metastatic colorectal cancer (mCRC) as determined by Food and Drug Administration-approved tests. A companion diagnostic, Therascreen KRAS RGQ PCR Kit for determining KRAS mutation status was approved concurrently with the cetuximab approval. The test is a real-time polymerase chain reaction assay that detects 7 mutations of the KRAS gene; tumors with none of these mutations are considered wild-type KRAS tumors.
*For PDFs of the full article and accompanying Commentary, click on the links to the left of this introduction.